PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Ranibizumab for Neovascular Age-Related Macular Degeneration

Real-world use of ranibizumab for neovascular age-related macular degeneration in Taiwan

PDF) Current and Novel Therapeutic Approaches for Treatment of Neovascular Age-Related Macular Degeneration

Biomolecules, Free Full-Text

Treatment Frequency and Dosing Interval of Ranibizumab and Aflibercept for Neovascular Age-Related Macular Degeneration in Routine Clinical Practice in the USA

PDF) Real-world variability in ranibizumab treatment and associated clinical, quality of life, and safety outcomes over 24 months in patients with neovascular age-related macular degeneration: The HELIOS study

Frontiers Cost-Effectiveness of Conbercept vs. Ranibizumab for Age-Related Macular Degeneration, Diabetic Macular Edema, and Pathological Myopia: Population-Based Cohort Study and Markov Model

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration

Functional versus functional and anatomical criteria-guided ranibizumab treatment in patients with neovascular age-related macular degeneration – results from the randomized, phase IIIb OCTAVE study, BMC Ophthalmology

Ranibizumab and Bevacizumab for Neovascular Age-Related Macular Degeneration